2. Search Result
Search Result
Results for "

human SH-SY5Y

" in MedChemExpress (MCE) Product Catalog:

61

Inhibitors & Agonists

4

Fluorescent Dyes

3

Biochemical Assay Reagents

1

Peptides

1

Inhibitory Antibodies

9

Natural
Products

3

Isotope-Labeled Compounds

2

Click Chemistry

1

Oligonucleotides

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0303
    Idebenone
    5+ Cited Publications

    		 Mitochondrial Metabolism Apoptosis Neurological Disease
    Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.
    Idebenone
  • HY-10974
    MK-0752
    10+ Cited Publications

    		 γ-secretase Neurological Disease Cancer
    MK-0752 is a potent, orally active and specific γ-secretase inhibitor, showing dose-dependent reduction of Aβ40 with an IC50 of 5 nM in human SH-SY5Y cells. MK-0752 crosses the blood-brain barrier. MK-0752 reduces newly generated CNS Aβ in vivo .
    MK-0752
  • HY-13438
    AZD3839 free base
    2 Publications Verification

    		 Beta-secretase Neurological Disease
    AZD3839 is an orally available, selective, reversible inhibitor of the β-site amyloid precursor protein cleaving enzyme BACE1 that can cross the blood-brain barrier. AZD3839 inhibits recombinant human BACE1 with a Ki=26.1 nM. AZD3839 inhibits A40 production in SH-SY5Y cells with an IC50 of 4.8 nM. AZD3839 binds to BACE1 and reduces the Aβ amyloid produced by the cleavage of amyloid precursor protein (APP) by BACE1 and γ-secretase. AZD3839 can be used in the field of Alzheimer's disease research .
    AZD3839 free base
  • HY-W010201
    Citronellol
    2 Publications Verification

    (±)-Citronellol; (±)-β-Citronellol

    		 Environmental Pollutants Necroptosis Autophagy Fungal Reactive Oxygen Species (ROS) ERK Atg8/LC3 TNF Receptor Apoptosis PI3K p62 Cardiovascular Disease Neurological Disease Cancer
    Citronellol ((±)-Citronellol) is an orally active inducer of apoptosis. Citronellol can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis .
    Citronellol
  • HY-N2392
    Kukoamine A
    1 Publications Verification

    		 Parasite Lipoxygenase Opioid Receptor Apoptosis Autophagy Reactive Oxygen Species (ROS) Interleukin Related TNF Receptor PGE synthase COX Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Kukoamine A, a spermine alkaloid, is an orally active and brain-penetrant component found in the root barks of Lycium chinense (L. chinense) Miller. Kukoamine A inhibits purified Crithidia fasciculata trypanothione reductase and soybean lipoxygenase, activates μ-opioid receptor. Kukoamine A can inhibt cancer cell proliferation, migration and invasion, cause G0/G1 phase cell cycle arrest and induce apoptosis. Kukoamine A exerts neuroprotective effect and can induce autophagy . Kukoamine A inhibits LPS (HY-D1056)-induced NO, ROS, PGE2, TNF-α, IL-1β, IL-6 production and COX-2 activity. Kukoamine A reverses palmitic acid-induced insulin resistance, lipid accumulation, and oxidative stress via downregulation of Srebp-1c. Kukoamine A can be used for the research of cancer, infection, inflammation, metabolic and neurological disease, such as glioblastoma and Parkinson's disease .
    Kukoamine A
  • HY-N6013
    Aloin (mixture of A&B)

    		MMP Proteasome Keap1-Nrf2 TGF-beta/Smad Interleukin Related SOD Bacterial Fungal Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Aloin (mixture of A&B) is an orally active anthraquinone derivative isolated from Aloe vera. Aloin (mixture of A&B) mitigates airway impairment and exerts neuroprotective, anti-inflammatory, antioxidant, antibacterial, antifungal, antiviral and antitumor effects. Aloin (mixture of A&B) inhibits Clostridium histolyticum collagenase, granulocyte matrix metalloproteinases and human 20S proteasome. Aloin (mixture of A&B) upregulates the Nrf2/HO-1 pathway, suppresses the TGF-β/Smad2/3 pathway. Aloin (mixture of A&B) reduces IL-4/IL-5/IL-13 levels, and reverses oxidative stress markers (MDA, SOD, GSH). Aloin (mixture of A&B) can be used for research on chronic ulcers, burns, wounds, inflammatory and degenerative disorders, asthma and neuroblastoma .
    Aloin (mixture of A&B)
  • HY-W143216
    Azure C

    Monomethylthionine

    		 Amyloid-β Tau Protein Neurological Disease
    Azure C acts as a tau oligomer modulator and Aβ42 oligomerization inhibitor. It regulates hsp70 ATPase activity, thereby mediating the clearance of tau protein. Azure C reduces the levels of toxic tau oligomers by promoting the formation of non-toxic tau aggregates, rescues neuroblastoma cells from tau oligomer-induced toxicity, and binds to and inhibits Aβ42 oligomerization without suppressing its fibrillization. Azure C is generated via sequential oxidation of methylene blue or Azure B through a horseradish peroxidase-mediated reaction, and accumulates in HRP reaction media. Azure C can be used in studies related to tauopathies, including Alzheimer's disease .
    Azure C
  • HY-B0512
    Sulfamerazine
    4 Publications Verification

    RP2632

    		 Antibiotic Bacterial α-synuclein Infection Neurological Disease
    Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection .
    Sulfamerazine
  • HY-136832
    Noribogaine hydrochloride

    		Serotonin Transporter Potassium Channel Arrestin Opioid Receptor Cardiovascular Disease Neurological Disease
    Noribogaine hydrochloride is an orally active, blood-brain barrier permeable SERT inhibitor (IC50=50-300 nM) and hERG channel blocker. Noribogaine hydrochloride enhances serotonergic transmission, activates the κ-opioid receptor (OPRK) G protein signaling pathway and inhibits β-arrestin recruitment. Meanwhile, Noribogaine hydrochloride blocks the μ-opioid receptor (OPRM) signaling pathway as well as ion channels associated with cardiac repolarization. Noribogaine hydrochloride induces neuritogenesis, upregulates GDNF mRNA expression, and modulates opioid tolerance. Noribogaine hydrochloride reduces alcohol-seeking behavior in experimental animals, and is widely used in studies related to depression, addiction, alcoholism, and cardiotoxicity .
    Noribogaine hydrochloride
  • HY-118020A
    Loliolide

    Loliolid; Digiprolactone

    		 Endogenous Metabolite Caspase PI3K Apoptosis Akt Sirtuin Reactive Oxygen Species (ROS) NF-κB MMP Neurological Disease Cancer
    Loliolide (Loliolid) is a β-carotene metabolite. Loliolide reduces caspase 3, 8, 9 expression, enhances PI3K, AKT, SIRT1, inhibits ROS, apoptosis, and blocks NF-κB p65 nuclear translocation. Loliolide protects mitochondria, reduces oxidative stress, and increases cell viability in neuroblastoma cells. Loliolide can be used for the research of UV-induced skin damage and Parkinson’s disease .
    Loliolide
  • HY-15141G
    Staurosporine

    Antibiotic AM-2282; STS; AM-2282

    		 PKC Infection Cancer
    Staurosporine (AM-2282) (GMP) is Staurosporine (HY-15141) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Staurosporine is a potent, ATP-competitive and non-selective inhibitor of protein kinases .
    Staurosporine
  • HY-N0046
    Notoginsenoside Fe

    Notoginseng triterpenes; Ginsenoside Mb

    		 Apoptosis Src Neurological Disease Metabolic Disease Cancer
    Notoginsenoside Fe (Notoginseng triterpenes; Ginsenoside Mb) is a saponin with anti-obesity and anti-neuroblastoma activities. Notoginsenoside Fe can be isolated from leaves of Panax notoginseng. Notoginsenoside Fe specifically activates paraventricular nucleus neurons in the hypothalamus, effectively reducing body weight, improving fasting blood glucose and protecting liver function by decreasing food intake, increasing resting metabolic rate and enhancing energy expenditure. Notoginsenoside Fe also inhibits the c-Src signaling pathway, blocks the proliferation and viability of human neuroblastoma cells, while improving mitochondrial dysfunction and alleviating apoptosis. Notoginsenoside Fe can be used in studies related to diet-induced obesity and neuroblastoma .
    Notoginsenoside Fe
  • HY-119357
    TN-16

    		Microtubule/Tubulin Apoptosis Autophagy Neurological Disease Cancer
    TN-16 is a Microtubule polymerization inhibitor. TN-16 induces G2/M cell cycle arrest, metaphase mitotic arrest and Apoptotic cell death in cells, and blocks late Autophagic flux by inhibiting autophagosome-lysosome fusion. TN-16 suppresses tumor growth in syngeneic mouse breast cancer models. TN-16 can be used in research related to neuroblastoma, cervical cancer, breast cancer and other tumors .
    TN-16
  • HY-119435
    Triallate

    		Herbicide Environmental Pollutants Others
    Triallate is a selective thiocarbamate herbicide. Triallate regulates the biosynthesis of very-long-chain fatty acids and inhibits the elongation and division of plant cells. Triallate is used to control wild oats in barley, spring wheat, durum wheat, winter wheat and sugar beets .
    Triallate
  • HY-N0143A
    Phlorizin dihydrate
    10+ Cited Publications

    Floridzin dihydrate

    		 SGLT PI3K Akt GLUT NF-κB JAK STAT Caspase Apoptosis DNA/RNA Synthesis mTOR Bacterial Infection Neurological Disease Metabolic Disease Cancer
    Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin dihydrate promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities .
    Phlorizin dihydrate
  • HY-172705
    DSPE-PEG2000-RVG29

    		Liposome nAChR Neurological Disease
    DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions .
    DSPE-PEG2000-RVG29
  • HY-P5894
    human GALP (3-32)

    Galanin-like peptide (3-32)

    		 Neuropeptide Y Receptor Neurological Disease
    human GALP (3-32) (Galanin-like peptide (3-32)) is a potent galanin receptor agonist with high affinity for both GalR1 (IC50=33 nM) and GalR2 (IC50=15 nM) in a competitive binding study. human GALP (3-32) exhibits the high potency in altering the extracellular acidification rate of SH-SY5Y cells transfected with GalR2 (EC50=360 nM) .
    human GALP (3-32)
  • HY-179177
    AO-365/43472821

    		DYRK CDK Tau Protein Amyloid-β Neurological Disease
    AO-365/43472821 is a selective, brain-penetrant Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor (IC50 = 0.29 μM) and shows a significant inhibitory effect on (CDC-like kinase 1) CLK1 (IC50 = 0.08 μM). AO-365/43472821 could protect the human neuroblastoma cell line SH-SY5Y from Okadaic acid (HY-N6785) (OA)-induced injury. AO-365/43472821 decreased tau (pSer396)/tau and Aβ1-42 protein expression. AO-365/43472821 can be used for the study of Alzheimer's disease .
    AO-365/43472821
  • HY-W010201R
    Citronellol (Standard)
    2 Publications Verification

    (±)-Citronellol (Standard); (±)-β-Citronellol (Standard)

    		 Reactive Oxygen Species (ROS) Reference Standards ERK PI3K TNF Receptor Atg8/LC3 p62 Apoptosis Necroptosis Autophagy Fungal Cardiovascular Disease Neurological Disease Cancer
    Citronellol (Standard) is the analytical standard of Citronellol. Citronellol (Standard) is an orally active inducer of apoptosis. Citronellol (Standard) can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol (Standard) can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol (Standard) can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol (Standard) exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis .
    Citronellol (Standard)
  • HY-W777283
    Idebenone-13C,d3

    		Isotope-Labeled Compounds Apoptosis Mitochondrial Metabolism Neurological Disease
    Idebenone- 13C,d3 is the deuterium labeled and 13C-labeled Idebenone (HY-N0303). Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.
    Idebenone-13C,d3
  • HY-W207699
    MAO-B-IN-46

    		Monoamine Oxidase Amylases Neurological Disease Metabolic Disease Inflammation/Immunology
    MAO-B-IN-46 (Compound 16) is a selective hMAO-B inhibitor (IC50: 26.8 nM), with weak activity against hMAO-A (IC50: 7.2054 μM). MAO-B-IN-46 (Compound 8) also acts as an α-amylase inhibitor (IC50: 19.46 μM). MAO-B-IN-46 exhibits certain neuroprotective effects and shows no significant toxicity to human gingival fibroblasts and SH-SY5Y cells. Additionally, MAO-B-IN-46 can scavenge DPPH and ABTS free radicals, with IC50 values of 17.86 μM and 17.71 μM, respectively. MAO-B-IN-46 can be used in the research of neurodegenerative diseases such as Parkinson's disease, diabetes, and diseases related to oxidative stress resistance .
    MAO-B-IN-46
  • HY-144635
    Nrf2-ARE/hMAO-B/QR2 modulator 1

    		Monoamine Oxidase Keap1-Nrf2 Reactive Oxygen Species (ROS) Neurological Disease
    Nrf2-ARE/hMAO-B/QR2 modulator 1 is a Resveratrol-based multitarget-directed ligands with IC50s of 8.05, 9.83 and 0.57 μM for hMAO-B, NRF2 and QR2. Nrf2-ARE/hMAO-B/QR2 modulator 1 has neuroprotection, decreasing ROS production in okadaic acid-treated mice hippocampal slices . Nrf2-ARE/hMAO-B/QR2 modulator 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Nrf2-ARE/hMAO-B/QR2 modulator 1
  • HY-178997
    NFE2L1 activator-1

    		Ferroptosis Glutathione Peroxidase Cancer
    NFE2L1 activator-1 (Compound 5b) is a potent nuclear factor erythroid 2-related factor 1 (NFE2L1) activator (EC50 = 2.4 µM). NFE2L1 activator-1 effectively resists ferroptosis (Ferroptosis). NFE2L1 activator-1 can specifically activate the NFE2L1 signaling pathway to upregulate GPX4, PSMB7, PSMC4. NFE2L1 activator-1 can be used in cancer research .
    NFE2L1 activator-1
  • HY-13438A
    AZD3839 fumarate

    		Beta-secretase Cancer
    AZD3839 fumarate is an orally available, selective, reversible inhibitor of the β-site amyloid precursor protein cleaving enzyme BACE1 that can cross the blood-brain barrier. AZD3839 fumarate inhibits recombinant human BACE1 with a Ki=26.1 nM. AZD3839 fumarate inhibits A40 production in SH-SY5Y cells with an IC50 of 4.8 nM. AZD3839 fumarate binds to BACE1 and reduces the Aβ amyloid produced by the cleavage of amyloid precursor protein (APP) by BACE1 and γ-secretase. AZD3839 fumarate can be used in the field of Alzheimer's disease research .
    AZD3839 fumarate
  • HY-139708
    NMDA receptor antagonist-3

    		iGluR Neurological Disease
    NMDA receptor antagonist-3, a NMDA receptor antagonist, stands out with a remarkable percentage of recovery (40.0%, at 100 μM) and safe toxicological profile in SH-SY5Y and human adipose mesenchymal stem cells.
    NMDA receptor antagonist-3
  • HY-161156
    BChE-IN-26

    		Cholinesterase (ChE) Neurological Disease Cancer
    BChE-IN-26 (Compound 7b) is a selective AChE and BChE inhibitor with Ki value of 35 μM and 1.6 μM. BChE-IN-26 has cytotoxicity to human neuroblastoma (SH-SY5Y) cell line. BChE-IN-26 can be used for the research of Alzheimer’s disease .
    BChE-IN-26
  • HY-18112
    AZ-4217

    		Beta-secretase Neurological Disease
    AZ-4217 is an inhibitor for β-site amyloid precursor protein cleavage enzyme 1 (BACE1), with IC50 of 160 pM in human SH-SY5Y cells. AZ-4217 reduces amyloid deposition in Tg2576 mouse models, and is used for Alzheimer’s Disease research .
    AZ-4217
  • HY-N0303R
    Idebenone (Standard)

    		Reference Standards Mitochondrial Metabolism Apoptosis Neurological Disease
    Idebenone (Standard) is the analytical standard of Idebenone. This product is intended for research and analytical applications. Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC50=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.
    Idebenone (Standard)
  • HY-155466
    Boc-MIF-1-Am

    		Dopamine Receptor Neurological Disease
    Boc-MIF-1-Am (compound 2) is a human dopamine D2 receptor enhancer (EC50=17.82 nM) and is a bioconjugate of melanostatin (MIF-1) and amantadine. Boc-MIF-1-Am (200 μM) exhibited mild neurotoxicity in SH-SY5Y cells .
    Boc-MIF-1-Am
  • HY-10975
    MK-0752 sodium

    		γ-secretase Neurological Disease Cancer
    MK-0752 sodium is a potent, orally active and specific γ-secretase inhibitor, showing dose-dependent reduction of Aβ40 with an IC50 of 5 nM in human SH-SY5Y cells. MK-0752 sodium crosses the blood-brain barrier. MK-0752 sodium reduces newly generated CNS Aβ in vivo .
    MK-0752 sodium
  • HY-162860
    FO-4-15

    		mGluR CaMK Tau Protein Neurological Disease
    FO-4-15 is an mGluR1/CaMKIIα activator. FO-4-15 has a protective effect against H2O2 in human neuroblastoma (SH-SY5Y) cells. FO-4-15 can improve cognitive impairment in Alzheimer’s disease mice by activating the mGluR1/CaMKIIα pathway, and can reduce Aβ accumulation, hyperphosphorylated Tau, and synaptic damage .
    FO-4-15
  • HY-172544
    TTBK1/2-IN-3

    		Tau Protein Neurological Disease
    TTBK1/2-IN-3 (Compound 10) is a potent inhibitor of tau tubulin kinase 1 (TTBK1) and TTBK2, with IC50 values of 579 nM and 258 nM, respectively. TTBK1/2-IN-3 inhibits the phosphorylation of TDP-43. TTBK1/2-IN-3 reduces the expression of primary cilia on the surface of iPSCs .
    TTBK1/2-IN-3
  • HY-118041
    PMPMEase-IN-1

    		Carboxylesterase (CES) Endogenous Metabolite Cancer
    PMPMEase-IN-1 is an allylated methylated protein methylesterase inhibitor with the property of inhibiting PMPMEase activity. PMPMEase-IN-1 may provide a useful strategy for cancer inhibition by enhancing its affinity for polyisoprenyl derivatives. PMPMEase-IN-1 showed the potential to have an effective concentration (EC50) value in causing degeneration of human neuroblastoma SH-SY5Y cells. Specific inhibition of PMPMEase-IN-1 may help regulate the metabolism of polyisoprenyl proteins and thus maintain normal cell survival. Further development and application of PMPMEase-IN-1 may open up new avenues for inhibiting degenerative diseases and cancer .
    PMPMEase-IN-1
  • HY-126638
    Marcfortine A

    NSC 324645

    		 Parasite Infection
    Marcfortine A is an indole alkaloid originally isolated from P. roqueforti. It has nematocidal activity against the parasitic nematode H. contortus (LD99=0.06 μg/mL) and inhibits motility of adult worms (EC50=2 μM). Marcfortine A eliminates H. contortus, T. colubriformis, and O. ostertagi from experimentally infected jirds (ED95s=0.33, 0.11, and 2.5 mg/animal, respectively). It dose-dependently inhibits nicotine-induced calcium mobilization in SH-SY5Y and TE-671 cells expressing α3 subunit-containing human nicotinic acetylcholine receptors (nAChRs) and muscle-type nAChRs, respectively.
    Marcfortine A
  • HY-W010201S
    Citronellol-d6

    (±)-Citronellol-d6; (±)-β-Citronellol-d6

    		 Reactive Oxygen Species (ROS) Isotope-Labeled Compounds Cancer
    Citronellol-d6 is deuterated labeled Citronellol (HY-W010201). Citronellol ((±)-Citronellol) is an orally active inducer of apoptosis. Citronellol can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis .
    Citronellol-d6
  • HY-119612
    XCT0135908

    XCT

    		 Nuclear Hormone Receptor 4A/NR4A RAR/RXR Neurological Disease
    XCT0135908 (XCT) is a selective Nurr1-RXRα activator with an EC50 value of 0.3 μM in human dopaminergic SH-SY5Y cells. XCT0135908 protects dopaminergic cells against the Parkinson’s disease-related toxin MPP +. XCT0135908 can be used for the research of Parkinson’s disease .
    XCT0135908
  • HY-163031
    MAO-B-IN-28

    		Monoamine Oxidase Neurological Disease
    MAO-B-IN-28 (compound 10e) is a potent hMAO-B inhibitor with an IC50 of 1.9±0.5 nM. MAO-B-IN-28 can be used as a candidate for neurodegenerative diseases research .
    MAO-B-IN-28
  • HY-W010201S1
    Citronellol-d3

    (±)-Citronelloll-d3; (±)-β-Citronelloll-d3

    		 Isotope-Labeled Compounds Fungal PI3K Apoptosis ERK Autophagy TNF Receptor Reactive Oxygen Species (ROS) Atg8/LC3 Necroptosis p62 Cardiovascular Disease Neurological Disease Cancer
    Citronellol-d3 ( (±)-Citronelloll-d3) is the deuterium labeled Citronellol (HY-W010201). Citronellol ((±)-Citronellol) is an orally active inducer of apoptosis. Citronellol can prevent oxidative stress, mitochondrial dysfunction, and apoptosis in the SH-SY5Y cell Parkinson's disease model induced by 6-OHDA by regulating the ROS-NO, MAPK/ERK, and PI3K/Akt signaling pathways. Citronellol can induce necroptosis in human lung cancer cells through the TNF-α pathway and accumulation of ROS. Citronellol can reduce the levels of LC-3 and p62 to regulate the autophagy pathway, inhibit oxidative stress and neuroinflammation, and thus have neuroprotective effects on Parkinson's rats. Citronellol exhibits anti-fungal activity against Trichophyton rubrum by inhibiting ergosterol synthesis .
    Citronellol-d3
  • HY-183750
    BChE reactivator-1

    		Cholinesterase (ChE) Metabolic Disease
    BChE reactivator-1 is a human butyrylcholinesterase (BChE) activator and antidote, with a Ki value of 0.52 μM against human BChE. BChE reactivator-1 activates BChE inhibited by organophosphorus compounds, binds reversibly to native BChE, and restores cholinesterase activity in human whole blood. BChE reactivator-1 is applicable to research related to organophosphorus poisoning .
    BChE reactivator-1
  • HY-182517
    AG1529

    		TRP Channel Inflammation/Immunology
    AG1529 is a TRPV1 inhibitor and capsaicinoid-based soft agent with a human TRPV1 IC50 of 0.9-0.93 μM. AG1529 reversibly blocks capsaicin-evoked TRPV1 activation, binds to the TRPV1 capsaicin binding site, moderately affects pH-induced TRPV1 gating, and does not alter voltage- or heat-mediated TRPV1 responses. AG1529 suppresses TRPV1-mediated neuronal excitability, reduces capsaicin- and pH-evoked neuronal firing, abolishes histaminergic and inflammation-mediated TRPV1 sensitization. AG1529 exhibits anti-nociceptive and antipruritic effects, attenuates in vivo hyperalgesia and pruritus, dose-dependently reduces acute histaminergic itch in rodents, and mildly blocks hTRPA1 and hTRPM8 channel activity. AG1529 undergoes hydrolysis and dermal deactivation, minimizes TRPV1-associated side reactions, does not evoke capsaicin-like burning sensation, and does not disrupt physiological thermal regulation. AG1529 can be used for the research of inflammatory cutaneous nociception and acute histaminergic pruritus .
    AG1529
  • HY-119399
    Salithion

    Dioxabenzofos

    		 Cholinesterase (ChE) Neurological Disease
    Salithion is an acetylcholinesterase inhibitor and neurotoxicant. Salithion binds to the active site of acetylcholinesterase to interfere with acetylcholine hydrolysis, and there is an enantioselective difference between its (R) and (S) enantiomers .
    Salithion
  • HY-183798
    BChE/MAO-B-IN-6

    		Cholinesterase (ChE) Monoamine Oxidase Interleukin Related Neurological Disease
    BChE/MAO-B-IN-6 is a dual inhibitor with inhibitory activity against both butyrylcholinesterase (BChE) and monoamine oxidase B (MAO B), with an IC50 of 557 nM against BChE and an IC50 of 142 nM against MAO B. BChE/MAO-B-IN-6 reduces IL-6 release from stimulated microglia and antagonizes 6-hydroxydopamine (HY-B1081) toxicity in neuroblastoma cells. BChE/MAO-B-IN-6 can be used in the research of neurodegenerative diseases .
    BChE/MAO-B-IN-6
  • HY-181268
    MAO-B-IN-53

    		Monoamine Oxidase Neurological Disease
    MAO-B-IN-53 is a human monoamine oxidase B (hMAO-B) inhibitor with an IC50 of 0.066 μM. MAO-B-IN-53 exhibits mixed reversible inhibition, binds stably to the hMAO-B active site, and shows high selectivity over hMAO-A. MAO-B-IN-53 acts as a neuroprotective agent, protects against 6-OHDA-induced damage, and exhibits low neurotoxicity in neuroblastoma cells. MAO-B-IN-53 can be used for the research of Parkinson's disease .
    MAO-B-IN-53
  • HY-N17468
    Neocrocin B

    		Neurological Disease
    Neocrocin B is a carotenoid crocin. Neocrocin B inhibits L-Glutamic acid (HY-14608)-induced neuronal cell damage in a dose-dependent manner. Neocrocin B can be used in studies related to neuronal injury .
    Neocrocin B
  • HY-182323
    SGK1-IN-7

    		SGK Tau Protein Neurological Disease
    SGK1-IN-7 is a blood-brain barrier-permeable SGK1 inhibitor with an IC50 of 0.72 μM. SGK1-IN-7 reduces the phosphorylation level of TAU protein at the Ser396 and Ser214 epitopes. SGK1-IN-7 antagonizes the toxicity induced by Okadaic acid (HY-N6785). SGK1-IN-7 can be used in the research of Alzheimer's disease .
    SGK1-IN-7
  • HY-182380
    ODZ10117

    		STAT NOD-like Receptor (NLR) Apoptosis Others Neurological Disease Inflammation/Immunology Cancer
    ODZ10117 is a STAT3 and NLRP3 inhibitor with a human STAT3 SH2 domain IC50 of 7.5 μM. ODZ10117 binds to the STAT3 SH2 domain, suppressing tyrosine phosphorylation, dimerization, nuclear translocation, and transcriptional activity. ODZ10117 binds to NLRP3, impairs NEK7 interaction, prevents inflammasome formation, and inhibits caspase-1 and IL-1β cleavage.ODZ10117 reduces MSU (HY-B2130A)-induced IL-1β release, lowers LPS (HY-D1056)-induced sepsis mortality, and exhibits anti-inflammatory effects. ODZ10117 induces apoptosis, suppresses breast cancer cell migration and invasion, reduces tumor growth and lung metastasis, and extends survival in breast cancer models. ODZ10117 can be used for the research of Monosodium urate (HY-B2130A)-induced peritonitis, LPS-induced sepsis, breast cancer, glioblastoma, and Alzheimer's disease .
    ODZ10117
  • HY-D3250
    PYSNO

    		Fluorescent Dye NO Synthase Cardiovascular Disease
    PYSNO is a lysosome-targeted fluorescent probe based on a pyridazinone skeleton (λem=515-565 nm, λex=405 nm) that can be used to track nitric oxide (NO) production in vivo. PYSNO exhibits a rapid, highly sensitive and highly selective "turn-on" response to endogenous and exogenous NO by blocking photoinduced electron transfer and regulating radiative decay rates. PYSNO enables precise in vivo monitoring in a mouse model of myocardial fibrosis and can be applied to the research of related diseases .
    PYSNO
  • HY-183325
    FTO-IN-17

    		Fat Mass and Obesity-associated Protein (FTO) CXCR TNF Receptor Neurological Disease
    FTO-IN-17 is an orally active and brain-penetrant FTO (m6A RNA demethylase) inhibitor with an IC50 of 1.1 μM. FTO-IN-17 stably binds the FTO catalytic pocket. FTO-IN-17 protects against Aβ1-42-induced toxicity while increasing global m6A levels and dampening pro-inflammatory gene (CXCL10, TNF-α) expression. FTO-IN-17 ameliorates anxiety-like behavior and rescues hippocampal-dependent spatial, recognition memory and neuroinflammation in Alzheimer's disease mice models .
    FTO-IN-17
  • HY-182042
    DENV-IN-15

    		Dengue Virus Infection
    DENV-IN-15 is a sulfonyl anthranilic acid derivative and a pan-serotype anti-dengue virus (DENV) inhibitor with broad-spectrum anti-RNA virus activity. The EC50 value of DENV-IN-15 against DENV-2 in Huh-7 cells is 0.7 μM. DENV-IN-15 selectively regulates the translation of mRNAs encoding translation-related proteins and containing a 5'-oligopyrimidine tract. DENV-IN-15 reduces the expression of specific ribosomal proteins, thereby inhibiting viral replication. DENV-IN-15 exhibits enhanced membrane permeability, human plasma stability and human liver microsomal metabolic stability. DENV-IN-15 is applicable to research related to dengue virus infection .
    DENV-IN-15
  • HY-183283
    CAII-IN-15

    		Carbonic Anhydrase Apoptosis NOD-like Receptor (NLR) Interleukin Related Reactive Oxygen Species (ROS) Neurological Disease
    CAII-IN-15 is a potent carbonic anhydrase II (CA II) inhibitor with a hCA II IC50 of 10 nM. CAII-IN-15 elevates cGMP levels, releases nitric oxide, reduces oxidative stress, and exhibits neuroprotective activity in vitro. CAII-IN-15 inhibits NLRP3 inflammasome activation, reduces neuronal apoptosis. CAII-IN-15 reduces Intraocular pressure (IOP) in rabbits. CAII-IN-15 can be used for the research of glaucoma .
    CAII-IN-15

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: